Terms: = Skin cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
1 results:
1. PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Sci Rep; 2021 May; 11(1):11023. PubMed ID: 34040017
[TBL] [Abstract] [Full Text] [Related]
